Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
Boehringer Ingelheim
Medtronic
McKesson

Last Updated: February 4, 2023

Ponesimod - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for ponesimod and what is the scope of freedom to operate?

Ponesimod is the generic ingredient in one branded drug marketed by Janssen Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ponesimod has one hundred and thirty-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for ponesimod
International Patents:133
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 41
Clinical Trials: 9
Patent Applications: 124
What excipients (inactive ingredients) are in ponesimod?ponesimod excipients list
DailyMed Link:ponesimod at DailyMed
Recent Clinical Trials for ponesimod

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Janssen Pharmaceutica N.V., BelgiumPhase 1
ActelionPhase 3
ActelionPhase 1

See all ponesimod clinical trials

US Patents and Regulatory Information for ponesimod

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-002 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-010 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-004 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-004 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-001 Mar 18, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-003 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Janssen Pharms PONVORY ponesimod TABLET;ORAL 213498-009 Mar 18, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ponesimod

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen-Cilag International N.V.    Ponvory ponesimod EMEA/H/C/005163
Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Authorised no no no 2021-05-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ponesimod

Country Patent Number Title Estimated Expiration
Spain 2352555 See Plans and Pricing
Malaysia 145074 THIAZOLIDIN-4-ONE DERIVATIVES See Plans and Pricing
Poland 3256125 See Plans and Pricing
Taiwan 201022220 Crystalline forms See Plans and Pricing
Japan 2012505873 See Plans and Pricing
Morocco 41481 RÉGIME POSOLOGIQUE POUR UN AGONISTE DE RÉCEPTEUR S1P1 SÉLECTIF See Plans and Pricing
Portugal 2344465 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ponesimod

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3256125 CA 2022 00026 Denmark See Plans and Pricing PRODUCT NAME: PONESIMOD (IUPAC NAME: (R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-OTOLYL-; REG. NO/DATE: EU/1/21/1550 20210521
3256125 PA2022505 Lithuania See Plans and Pricing PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125 122022000027 Germany See Plans and Pricing PRODUCT NAME: PONESIMOD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125 LUC00262 Luxembourg See Plans and Pricing PRODUCT NAME: PONESIMOD (NOM IUPAC : (R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE); AUTHORISATION NUMBER AND DATE: EU/1/21/1550 20210521
3256125 C03256125/01 Switzerland See Plans and Pricing PRODUCT NAME: PONESIMOD; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68114 16.11.2021
3256125 301174 Netherlands See Plans and Pricing PRODUCT NAME: PONESIMOD (IUPAC NAAM: (R)-5-(3-CHLOOR-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDEEN)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ON), DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/21/1550 20210521
3256125 2022C/515 Belgium See Plans and Pricing PRODUCT NAME: PONESIMOD (IUPAC NAAM: (R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)- BENZ(Z)YLIDEEN)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ON); AUTHORISATION NUMBER AND DATE: EU/1/21/1550 20210521
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Harvard Business School
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.